317 related articles for article (PubMed ID: 20059301)
1. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
3. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
6. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells.
Wang C; Ho PC; Lim LY
Int J Pharm; 2010 Nov; 400(1-2):201-10. PubMed ID: 20804835
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
8. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
Jin C; Bai L; Wu H; Tian F; Guo G
Biomaterials; 2007 Sep; 28(25):3724-30. PubMed ID: 17509678
[TBL] [Abstract][Full Text] [Related]
11. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
12. Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells.
Zhao YX; Liang WQ; Wang Y; Liu DX
Pharmazie; 2011 Feb; 66(2):130-5. PubMed ID: 21434576
[TBL] [Abstract][Full Text] [Related]
13. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action.
Zhang Y; Li H; Wang H; Su F; Qu R; Yin D; Dai J; Li Y; Chen X
Cancer Chemother Pharmacol; 2010 Oct; 66(5):851-9. PubMed ID: 20052473
[TBL] [Abstract][Full Text] [Related]
14. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Baek JS; Cho CW
Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
[TBL] [Abstract][Full Text] [Related]
15. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
Yadav S; van Vlerken LE; Little SR; Amiji MM
Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
17. Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug.
Jang MK; Jeong YI; Nah JW
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):530-6. PubMed ID: 20801624
[TBL] [Abstract][Full Text] [Related]
18. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery.
Bilensoy E; Gürkaynak O; Doğan AL; Hincal AA
Int J Pharm; 2008 Jan; 347(1-2):163-70. PubMed ID: 17689901
[TBL] [Abstract][Full Text] [Related]
20. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]